Find Faculty

Sacha Gnjatic, PhD

img_Sacha Gnjatic
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Pathology, Molecular and Cell Based Medicine
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Oncological Sciences
email
Research Topics
Anti-Tumor Therapy, Antigen Presentation, B Cells, Cancer, Cellular Immunity, Dendritic Cells, Immunological Tolerance, Immunology, Immunosuppression, Lung, Microarray, Proteomics, T Cells, Tolerance, Translation, Vaccine Development
Multi-Disciplinary Training Area
Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]
Mechanisms of antigen presentation to T cells:
Mechanisms of antigen presentation to and recognition by T cells, including defining epitopes, evaluating viral, bacterial, and parasitic vectors, cross-presentation of antigen to HLA class I, and endogenous antigen presentation to HLA class II.
Inflammatory diseases:
Role of GM-CSF autoantibodies throughout Crohn's disease development. Dissecting role of cytokines, antibody and T cell responses in COVID-19 patients after infection or vaccination.
Immune monitoring to discover mechanisms and biomarker of cancer immunotherapies:
Multiscale (host, circulation, tissues, single cell), multiomics (immunophenotyping, immunopathology, immunotranscriptomics, bioinformatics) approaches for biomarker discovery and understanding of mechanisms contributing to clinical responses, adverse events, or primary and acquired resistance to tumor immunotherapies.
Tissue immune microenvironment:
Assessment of the tumor microenvironment for immunocytes and suppressive signals, including development of novel spatial technologies to address in depth biomarkers at the tissue site.
Antigen-specific spontaneous and immunotherapy-induced tumor immunity:
Characterization of serological and cellular immune responses against tumor antigens such as NY-ESO-1, MAGE-A3, or p53, and for their capacity to induce immune responses both spontaneously and in the setting of cancer immunotherapy.
Impact of immunoregulation on tumor antigen-specific responses:
Impact of immunoregulation on tumor antigen-specific responses, from co-inhibitory molecules expressed on T cells at the tumor site to the effect of regulatory T cells on anti-tumor effectors, and study of immune tolerance.

BSc3, University College London

MSc, Institut Pasteur

Undergraduate, Ecole Normale Supérieure

PhD, University Paris VII

Post-doc, Memorial Sloan-Kettering - Ludwig Institute

278
Publications

Selected Publications

Integrated histopathology of the human pancreas throughout stages of type 1 diabetes progression. Verena van der Heide, Sara McArdle, Michael S. Nelson, Karen Cerosaletti, Sacha Gnjatic, Zbigniew Mikulski, Amanda L. Posgai, Irina Kusmartseva, Mark A. Atkinson, Dirk Homann. Nature Communications

A Tumor-Promoting Inflammatory SPP1<sup>+</sup> Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer. Michelle A. Tran, Byuri Angela Cho, Sudeh Izadmehr, Seong Keun Yoo, Dina Youssef, Jonathan F. Anker, Adam M. Farkas, Igor Figueiredo, Karen Lee, Aparna Ananthanarayanan, Sreekumar Balan, Sayali Onkar, Romain Banchereau, Saurabh Gupta, Aparna Chhibber, Li Wang, Kristin G. Beaumont, Ziao Li, Monica Garcia-Barros, Mesude Bicak, Carlos Cordon-Cardo, Rachel Brody, Seunghee Kim-Schulze, Kobe Yuen, Sanjeev Mariathasan, Saad O. Atiq, Tolulope T. Adeyelu, Andrew Elliott, Pedro Barata, Rana R. McKay, Sacha Gnjatic, Edgar Gonzalez-Kozlova, Reza Mehrazin, Amir Horowitz, John P. Sfakianos, Diego Chowell, Matthew D. Galsky, Nina Bhardwaj. Cancer Discovery

CD3 and PD-L1 tissue expression have synergistic value in head and neck squamous cell carcinoma prognosis. Adrian v. Witzleben, Romain Remark, Christian Idel, Julika Ribbat-Idel, Rosemarie Krupar, Andreas Schröck, Niklas Klümper, Johannes Doescher, Andrew G. Sikora, Tsima Abou Kors, Julius M. Vahl, Matthias Brand, Michael Sonntag, Cornelia Brunner, Thomas K. Hoffmann, Sven Perner, Sacha Gnjatic, Simon Laban. Translational Oncology

View All Publications

Hess CSM Building Floor 5 Room 105

1470 Madison Ave

New York, NY 10029

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Gnjatic during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Taiho Oncology, Inc
  • Memorial Sloan-Kettering Cancer Center
  • National Cancer Institute/NIH/DHHS
  • Society for Immunotherapy of Cancer
  • Gilead Sciences

Editorial Services

  • Cancer Immunology Research
  • Frontiers in Immunology

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.